ePoster
Die hochgeladenen ePoster sind nur für eingeloggte Teilnehmende ersichtlich.
Bitte loggen Sie sich ein, um zu den ePoster zu gelangen.
Detaillierte Beitrags-Information
| Beitragstitel | PreserFlo™ MicroShunt in combination with phacoemulsification versus phacoemulsification and local antiglaucomatous therapy in a patient with medically uncontrolled pigmentary glaucoma |
|---|---|
| Beitragscode | P60 |
| Autor:innen | |
| Präsentationsform | ePoster |
| Themengebiete |
|
| Abstract-Text |
Purpose: To compare the efficacy and safety of the PreserFlo™ MicroShunt (Santen, Osaka, Japan) in combination with phacoemulsification versus phacoemulsification in combination with local antiglaucomatous therapy in both eyes of a patient with moderate pigmentary glaucoma. Methods: To present a case report of a 74 year old male patient with moderate pigmentary glaucoma. One eye of the patient with preoperative IOP on maximal local therapy of 26 mmHg was treated with PreserFlo™ MicroShunt combined with phacoemulsification. The other eye with preoperative IOP of 23 mmHg on maximal local therapy underwent phacoemulsification and received postoperatively antiglaucomatous therapy. The topical medication postoperatively was the fixed combination of brinzolamide and brimonidine tartrate. The follow-up time of the patient was 1 year and 3 months. Results: The average intraocular pressure (IOP) at 12 months was 12 ± 1.6 mmHg in the eye with PreserFlo™ MicroShunt combined with phacoemulsification and 9 ±1.4 mmHg in the eye with phacomulsification combined with topical fixed combination drops. The absolute reduction of the IOP within the 12 postoperative months was not significantly different between the two eyes. The combined procedure of PreserFlo™ MicroShunt and phacoemulsification significantly reduced the IOP after 12 months as well as the phacoemulsification procedure combined with a local therapy. Within the period of observation there was no need of additional surgical procedures. The endothelial cell density did not significantly change over 12 months in both eyes. The PreserFlo™ MicroShunt combined with phacoemulsification showed no superiority over the phacoemulsification combined with local antiglaucomatous therapy. Nevetheless the patient was more satisfied with the eye without antiglaucomatous drops. Conclusions: In eyes with moderate pigmentary glaucoma, PreserFlo™ MicroShunt with phacoemulsification is effective in reducing IOP and the number of the antiglaucoma agents. Adding PreserFlo™ MicroShunt to phacoemulsification successfully reduces IOP without the need for ongoing topical medications as are needed after the phacoemulsification alone procedure. |